Norges Bank’s ADC Therapeutics ADCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-60,000
Closed -$1.92M 2130
2020
Q4
$1.92M Hold
60,000
﹤0.01% 1958
2020
Q3
$1.98M Buy
60,000
+50,000
+500% +$2.16M ﹤0.01% 1969
2020
Q2
$468K Buy
+10,000
New +$380K ﹤0.01% 2051

Other funds holding ADCT

Norges Bank's ADCT Position: Q1 2021 in Review

Norges Bank sold out of ADC Therapeutics (ADCT) in Q1 2021, closing a stake of 60,000 shares — an estimated $1.92M sold.

Norges Bank first reported a position in ADCT in Q2 2020 and held it in 3 quarters. The position peaked at $1.98M in Q3 2020. 59 funds tracked by Wall St. Rank hold ADCT as of Q1 2021.

  • Norges Bank reported no remaining ADC Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Norges Bank sold 60,000 ADC Therapeutics shares in Q1 2021, an estimated $1.92M.
  • Norges Bank first reported a position in ADC Therapeutics in Q2 2020 and held it in 3 quarters.
  • Norges Bank's ADC Therapeutics position peaked at $1.98M in Q3 2020.
  • 59 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2021.

Based on Norges Bank's 13F filing for Q1 2021, filed 7 May 2021.